EUVIMEDEUVIMED entdecken
Crossref

Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker

İsmail Alkaç, Murat İşbilen, Barış Küçükkaraduman, Ali Güre, Burçak Vural

Experimed · 2022

DOI: 10.26650/experimed.1082020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimed, 2022. Verfasst von İsmail Alkaç und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Alkaç, İ., İşbilen, M., Küçükkaraduman, B., Güre, A., & Vural, B. (2022). Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker. Experimed. https://doi.org/10.26650/experimed.1082020

Vancouver

Alkaç İ, İşbilen M, Küçükkaraduman B, Güre A, Vural B. Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker. Experimed. 2022. doi:10.26650/experimed.1082020

BibTeX
@article{Alka2022,
  author = {Alkaç, İsmail and İşbilen, Murat and Küçükkaraduman, Barış and Güre, Ali and Vural, Burçak},
  title = {Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker},
  journal = {Experimed},
  year = {2022},
  doi = {10.26650/experimed.1082020}
}
Kostenlos starten →